Discover Community Create You

Loading publication...

Noodle always counts identifier-free feature events for service operation. With your permission, Google Analytics can also estimate audience and engagement. Search text, publication identifiers, cookies, IP addresses and browser fingerprints are never included in Noodle's first-party event counters.

Privacy details

Article

SARS-CoV-2 variant B.1.617 is resistant to bamlanivimab and evades antibodies induced by infection and vaccination

29 Jun 2021

Abstract excerpt

The emergence of severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) variants threatens efforts to contain the coronavirus disease 2019 (COVID-19) pandemic. The number of COVID-19 cases and deaths in India has risen steeply, and a SARS-CoV-2 variant, B.1.617, is believed to be responsible for many of these cases. The spike protein of B.1.617 harbors two mutations in the receptor binding domain, which...

Read the complete abstract on PubMed

Topics

Share this publication in a Topic to start or enrich a Post.

Share to COVID-19 Clinical Research Studies
Share to SARS-CoV-2 and COVID-19 Research
Share to SARS-CoV-2 detection and testing

Methodology Data sources Editorial policy Privacy About Contact Helena Bioinformatics

Source

Identifiers

PMID: 34270919
DOI: 10.1016/j.celrep.2021.109415

Provenance

PubMed metadata and Literature Corpus relationships. Corpus snapshot updated 8 Sept 2026.

Related research

Semantic proximity does not establish scientific evidence.

Research trail→

Click a neighbor to travelStep 1 · 12 closest

SARS-CoV-2 variant B.1.617 is resistant to bamlanivimab and evades antibodies induced by infection and vaccinationPMID 34270919Read ↗

Reduced sensitivity of infectious SARS-CoV-2 variant B.1.617.2 to monoclonal antibodies and sera from convalescent and vaccinated individualsSemantic proximity Read ↗

SARS-CoV-2 B.1.617 emergence and sensitivity to vaccine-elicited antibodiesSemantic proximity Read ↗

Increased lung cell entry of B.1.617.2 and evasion of antibodies induced by infection and BNT162b2 vaccinationSemantic proximity Read ↗

SARS-CoV-2 B.1.617.2 Delta variant replication, sensitivity to neutralising antibodies and vaccine breakthroughSemantic proximity Read ↗

Impact of B.1.617 and RBD SARS-CoV-2 variants on vaccine efficacy: An in-silico approach.Semantic proximity Read ↗

Characterization of SARS-CoV-2 Variants B.1.617.1 (Kappa), B.1.617.2 (Delta), and B.1.618 by Cell Entry and Immune EvasionSemantic proximity Read ↗

BA.2.12.1, BA.4 and BA.5 escape antibodies elicited by Omicron infection.Semantic proximity Read ↗

An infectious SARS-CoV-2 B.1.1.529 Omicron virus escapes neutralization by several therapeutic monoclonal antibodiesSemantic proximity Read ↗

SARS-CoV-2 variants B.1.351 and B.1.1.248: Escape from therapeutic antibodies and antibodies induced by infection and vaccinationSemantic proximity Read ↗

Impact of B.1.617 and RBD SARS-CoV-2 Variants on Vaccine Efficacy: An In-silico ApproachSemantic proximity Read ↗

Antibody resistance of SARS-CoV-2 variants B.1.351 and B.1.1.7.Semantic proximity Read ↗

Antibody evasion by the P.1 strain of SARS-CoV-2.Semantic proximity Read ↗

⌁Select a neighboring publication to make it the new centre.